Fig. 1From: 4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry a Percentage of responders versus an improvement of FEV1, ACQ or OCS. b Percentage of non-responders versus an improvement of FEV1, ACQ or OCSBack to article page